Although multiple genetic mutations in RTKs, Ras, Raf, and MEK cause constitutive activation of the ERK1/2 pathway and drive many types of malignancies (46, 47), patients with prostate cancer frequently do not have these oncogenic mutations. This evidence concerns the gene MAPK3 and prostate cancer.